Becton Dickinson and Co (NYSE:BDX) Stake Raised by Wambolt & Associates LLC

Wambolt & Associates LLC increased its holdings in Becton Dickinson and Co (NYSE:BDX) by 41.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,550 shares of the medical instruments supplier’s stock after acquiring an additional 453 shares during the quarter. Wambolt & Associates LLC’s holdings in Becton Dickinson and were worth $387,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. IMS Capital Management purchased a new stake in Becton Dickinson and during the 3rd quarter valued at about $29,000. Nalls Sherbakoff Group LLC purchased a new stake in Becton Dickinson and during the 4th quarter valued at about $34,000. Aspire Private Capital LLC purchased a new stake in Becton Dickinson and during the 4th quarter valued at about $39,000. Sontag Advisory LLC purchased a new stake in Becton Dickinson and during the 4th quarter valued at about $43,000. Finally, JCIC Asset Management Inc. purchased a new stake in Becton Dickinson and during the 4th quarter valued at about $54,000. Institutional investors own 84.89% of the company’s stock.

In other news, CEO Vincent A. Forlenza sold 11,340 shares of the stock in a transaction that occurred on Monday, February 25th. The shares were sold at an average price of $250.40, for a total value of $2,839,536.00. Following the transaction, the chief executive officer now owns 227,250 shares in the company, valued at approximately $56,903,400. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Ribo Alberto Mas sold 2,104 shares of the stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $255.00, for a total transaction of $536,520.00. Following the completion of the transaction, the executive vice president now owns 19,074 shares in the company, valued at approximately $4,863,870. The disclosure for this sale can be found here. Insiders sold a total of 29,684 shares of company stock worth $7,518,574 in the last quarter. Company insiders own 0.12% of the company’s stock.

Several brokerages recently commented on BDX. Zacks Investment Research raised shares of Becton Dickinson and from a “sell” rating to a “hold” rating in a research report on Wednesday, April 10th. ValuEngine downgraded shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Monday, April 1st. Piper Jaffray Companies raised their price target on shares of Becton Dickinson and to $274.00 and gave the company an “overweight” rating in a report on Tuesday, February 5th. Barclays raised their price target on shares of Becton Dickinson and from $260.00 to $266.00 and gave the company an “equal weight” rating in a report on Monday, April 15th. Finally, TheStreet raised shares of Becton Dickinson and from a “c+” rating to an “a” rating in a report on Tuesday, February 5th. Six analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $256.25.

Shares of NYSE BDX traded up $1.22 during trading on Friday, reaching $237.89. 925,377 shares of the company traded hands, compared to its average volume of 1,202,144. The company has a quick ratio of 0.62, a current ratio of 0.97 and a debt-to-equity ratio of 0.83. The company has a market cap of $64.01 billion, a PE ratio of 21.61, a PEG ratio of 1.70 and a beta of 1.16. Becton Dickinson and Co has a 52-week low of $208.62 and a 52-week high of $265.87.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Tuesday, February 5th. The medical instruments supplier reported $2.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.58 by $0.12. Becton Dickinson and had a net margin of 5.69% and a return on equity of 14.65%. The firm had revenue of $4.16 billion for the quarter, compared to the consensus estimate of $4.10 billion. During the same quarter last year, the firm posted $2.48 EPS. The business’s quarterly revenue was up 35.1% compared to the same quarter last year. As a group, equities research analysts anticipate that Becton Dickinson and Co will post 12.07 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Friday, June 7th will be paid a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 1.29%. The ex-dividend date is Thursday, June 6th. Becton Dickinson and’s dividend payout ratio (DPR) is presently 27.97%.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/05/04/wambolt-associates-llc-buys-453-shares-of-becton-dickinson-and-co-bdx.html.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

See Also: How Important is Technical Analysis of Stocks

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.